Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Partially Randomized, 3 Treatment Groups, Multi-Site Study Assessing Pharmacokinetics After Administration of the Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) at Different Injection Sites in Opioid-Dependent Subjects With Chronic Pain

NCT02710526 is registered in ClinicalTrials.gov with Braeburn Pharmaceuticals as lead sponsor.

NCT NCT02710526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02710526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Partially Randomized, 3 Treatment Groups, Multi-Site Study Assessing Pharmacokinetics After Administration of the Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) at Different Injection Sites in Opioid-Dependent Subjects With Chronic Pain
Lead sponsor
Braeburn Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
July 3, 2017
Enrollment
66 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pain, opioid use disorder